Literature DB >> 27660215

Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets.

Alexandra Grubman1,2,3, Katja M Kanninen4, Tarja Malm4.   

Abstract

Given the importance of microglia to inflammatory, phagocytic and synaptic modulatory processes, their function is vital in physiological and pathological brain. The impairment of microglia in Alzheimer's disease has been demonstrated on genetic, epigenetic, transcriptional and functional levels using unbiased systems level approaches. Recent studies have highlighted the immense phenotypic diversity of microglia, including the ability to adopt distinct and dynamic phenotypes in ageing and disease. We review the origins and functions of healthy microglia and the established and emerging models and techniques available for their study. Furthermore, we highlight recent advances on the role, heterogeneity and dysfunction of microglia in Alzheimer's disease and discuss the potential for therapeutic interventions targeting microglia. Microglia-selective molecular fingerprints will guide detailed functional analysis of microglial subsets and may aid in the development of therapies specifically targeting microglia.

Entities:  

Keywords:  Alzheimer’s disease; Diversity; Heterogeneity; Microglia; Stem cell models; Therapeutic

Mesh:

Year:  2016        PMID: 27660215     DOI: 10.1007/s12031-016-0825-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  158 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

Review 2.  A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease.

Authors:  Monica J Carson; Tina V Bilousova; Shweta S Puntambekar; Benoit Melchior; Jonathan M Doose; Iryna M Ethell
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

3.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation.

Authors:  Hirohide Asai; Seiko Ikezu; Satoshi Tsunoda; Maria Medalla; Jennifer Luebke; Tarik Haydar; Benjamin Wolozin; Oleg Butovsky; Sebastian Kügler; Tsuneya Ikezu
Journal:  Nat Neurosci       Date:  2015-10-05       Impact factor: 24.884

Review 4.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

5.  CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model.

Authors:  Marius Krauthausen; Markus P Kummer; Julian Zimmermann; Elisabet Reyes-Irisarri; Dick Terwel; Bruno Bulic; Michael T Heneka; Marcus Müller
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

6.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

Review 7.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

8.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

9.  Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin.

Authors:  Milan Fiala; Philip T Liu; Araceli Espinosa-Jeffrey; Mark J Rosenthal; George Bernard; John M Ringman; James Sayre; Laura Zhang; Justin Zaghi; Sheila Dejbakhsh; Ben Chiang; James Hui; Michelle Mahanian; Anita Baghaee; Pamela Hong; John Cashman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

10.  Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.

Authors:  Adrian Olmos-Alonso; Sjoerd T T Schetters; Sarmi Sri; Katharine Askew; Renzo Mancuso; Mariana Vargas-Caballero; Christian Holscher; V Hugh Perry; Diego Gomez-Nicola
Journal:  Brain       Date:  2016-01-08       Impact factor: 13.501

View more
  6 in total

1.  Dementia Research Australia: the Australian Dementia Research Development Fellowship Program.

Authors:  Ashley I Bush; George Fink; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-11       Impact factor: 3.444

2.  Epigenetic Promoter DNA Methylation of miR-124 Promotes HIV-1 Tat-Mediated Microglial Activation via MECP2-STAT3 Axis.

Authors:  Palsamy Periyasamy; Annadurai Thangaraj; Ming-Lei Guo; Guoku Hu; Shannon Callen; Shilpa Buch
Journal:  J Neurosci       Date:  2018-05-14       Impact factor: 6.167

3.  Transcriptional signature in microglia associated with Aβ plaque phagocytosis.

Authors:  Alexandra Grubman; Xin Yi Choo; Gabriel Chew; John F Ouyang; Guizhi Sun; Nathan P Croft; Fernando J Rossello; Rebecca Simmons; Sam Buckberry; Dulce Vargas Landin; Jahnvi Pflueger; Teresa H Vandekolk; Zehra Abay; Yichen Zhou; Xiaodong Liu; Joseph Chen; Michael Larcombe; John M Haynes; Catriona McLean; Sarah Williams; Siew Yeen Chai; Trevor Wilson; Ryan Lister; Colin W Pouton; Anthony W Purcell; Owen J L Rackham; Enrico Petretto; Jose M Polo
Journal:  Nat Commun       Date:  2021-05-21       Impact factor: 14.919

Review 4.  An updated assessment of microglia depletion: current concepts and future directions.

Authors:  Jinming Han; Robert A Harris; Xing-Mei Zhang
Journal:  Mol Brain       Date:  2017-06-19       Impact factor: 4.041

Review 5.  The Role of LRRK2 in Neurodegeneration of Parkinson Disease.

Authors:  Qin Rui; Haibo Ni; Di Li; Rong Gao; Gang Chen
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 6.  Microglia in neurodegenerative diseases.

Authors:  Yu Xu; Ming-Zhu Jin; Ze-Yong Yang; Wei-Lin Jin
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.